Suppr超能文献

接种 ChAdOx1 nCoV-19 新冠疫苗后出现全身性水肿和假性血小板减少症:1 例病例报告。

Generalized Edema and Pseudothrombocytopenia After ChAdOx1 nCoV-19 COVID-19 Vaccination: A Case Report.

机构信息

Department of Hematology, Instituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz (FIOCRUZ), Rio de Janeiro, Brazil.

Onco-Hematology Unit, Clínica São Vicente, Rio de Janeiro, Brazil.

出版信息

Front Public Health. 2022 May 27;10:907652. doi: 10.3389/fpubh.2022.907652. eCollection 2022.

Abstract

Reports of side effects of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are increasing worldwide. Capillary leak syndrome and vaccine-induced immune thrombotic thrombocytopenia are very rare but life-threatening adverse events that should be identified early and treated. However, isolated thrombocytopenia can indicate pseudothrombocytopenia. In certain people, ethylenediaminetetraacetic acid (EDTA) induces an platelet aggregation, resulting in misleading underestimation of platelet counts. It is essential to recognize pseudothrombocytopenia to prevent diagnostic errors, overtreatment, anxiety, and unnecessary invasive procedures. We present a case who developed generalized edema and persistent pseudothrombocytopenia after the first dose of the ChAdOx1 nCoV-19 vaccine (AstraZeneca).

摘要

全球范围内,关于严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)疫苗副作用的报告越来越多。毛细血管渗漏综合征和疫苗诱导的免疫性血栓性血小板减少症是非常罕见但危及生命的不良事件,应及早识别并进行治疗。但是,孤立性血小板减少症可能提示假性血小板减少症。在某些人群中,乙二胺四乙酸(EDTA)会诱导血小板聚集,导致血小板计数被错误地低估。识别假性血小板减少症对于预防诊断错误、过度治疗、焦虑和不必要的有创性操作至关重要。我们报告了一例在接种第一剂腺病毒载体新冠疫苗(阿斯利康)后出现全身性水肿和持续假性血小板减少症的病例。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35c7/9184712/978a8b6526d5/fpubh-10-907652-g0001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验